ASO Author Reflections: Serum IgA as a Predictive Biomarker for Immunotherapy in Esophageal Squamous Cell Carcinoma

Kosaku Torii, Akimitsu Iizuka, Mitsuro Kanda · 2026

Read ASO Author Reflections: Serum IgA as a Predictive Biomarker for Immunotherapy in Esophageal Squamous Cell Carcinoma by Kosaku Torii, Akimitsu Iizuka, Mitsuro Kanda (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13585837.txt.

Introduction

Kosaku Torii, Akimitsu Iizuka, and Mitsuro Kanda reflect on a blood antibody that may forecast immunotherapy results in esophageal cancer. The cancer type, squamous cell carcinoma of the food pipe, is often found late and tends to return. Immune checkpoint drugs are a first-line choice when it cannot be cut out. Still, some patients worsen fast on them, and doctors lack a cheap way to spot those patients ahead of time.

Their linked study measured an antibody called IgA in the blood of 20 patients before treatment. Patients with high IgA responded only rarely, while seven in ten with low IgA responded, and their disease also stayed quiet for less time. The authors note the test is cheap and easy to repeat, but the group was small, so larger studies must confirm the signal.

Catalog record

CREATORKosaku Torii, Akimitsu Iizuka, Mitsuro Kanda
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE3260
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13585837

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

ASO Author Reflections: Serum IgA as a Predictive Biomarker for Immunotherapy in Esophageal Squamous Cell Carcinoma
Authors: Kosaku Torii, Akimitsu Iizuka, Mitsuro Kanda
Published: 2026

Past

Esophageal squamous cell carcinoma (ESCC) is frequently diagnosed at advanced stages and demonstrates a high rate of recurrence even after curative resection.1 In Japan, current clinical practice guidelines recommend the use of immune checkpoint inhibitors (ICIs) as a first-line therapy for unresectable ESCC. However, early disease progression after the initiation of ICI therapy has emerged as a major clinical concern, underscoring the urgent need for reliable predictive biomarkers.

While Immunoglobulin A (IgA) is well recognized as the principal antibody mediating mucosal immunity in the gastrointestinal and respiratory tracts, about 10 % of IgA circulates in the bloodstream and contributes to systemic immune responses.2 However, few studies have examined the relationship between serum IgA levels and systemic therapy for solid tumors, and reports linking serum IgA to the efficacy of ICIs are particularly scarce. To date, no study has investigated the association between serum IgA levels and ICI treatment outcomes in ESCC.

Present

In this study, we evaluated the association between pretreatment serum IgA levels and survival outcomes in patients with unresectable ESCC receiving first-line ICI therapy. The overall response rate was 10% in the high IgA group, compared with 70% in the low IgA group. Furthermore, progression-free survival (PFS) was significantly shorter in the high IgA group than in the low IgA group.3

Serum IgA offers several distinct advantages as a clinical tool: it is minimally invasive, low-cost, easily accessible using routine blood samples, and feasible for repeated assessment throughout the treatment course. Our findings demonstrate that pretreatment serum IgA levels can serve as a novel and practical predictive biomarker for unresectable ESCC, potentially optimizing patient selection for immunotherapy.

Future

Our study is limited by a small sample size of 20 patients and a relatively short observation period. Therefore, future large-scale studies with extended follow-up are warranted to validate our findings. On the basis of previous literature,4 we speculate that high serum IgA levels may indirectly reflect an immunosuppressive tumor microenvironment (TME) which contributes to poor ICI efficacy; however, this remains a hypothesis. Further histopathological and immunological investigations are required to elucidate the underlying mechanisms within the TME, ultimately paving the way for personalized immunotherapy strategies in advanced ESCC.

Funding

Open Access funding provided by Nagoya University.

Disclosure

All authors have no conflicts of interest to disclose.

Footnotes

This article refers to: Torii K, Iizuka A, Kanda M, et al. High serum IgA identifies poor responders to immune checkpoint inhibitors in patients with unresectable esophageal squamous cell carcinoma. Ann Surg Oncol. 2026. https://doi.org/10.1245/s10434-026-19879-5.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Read the complete text